Funding Opportunities

Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.

CRDFGlobal RFP Announced: Cross Consortium Funding for the RePORT International Consortium

The RePORT International Coordinating Center (RICC) invites researchers to submit full proposals for the Cross Consortium Funding for the RePORT International Consortium. This initiative will provide a maximum of two (2) years of funding to support two (2) to three (3) projects to support the development of collaborations across the RePORT consortium. This competition is organized by the RICC and administered by CRDF Global on behalf of the National Institute of Allergies and Infectious Diseases (NIAID).   

Full proposals must be submitted to CRDF Global’s Cross Consortium intake inbox no later than Friday, June 21, 2024 (23:59) U.S. Eastern Standard Time (EST). Proposals will undergo a round of peer evaluation. 

Please visit CRDF Global’s website to view the request for proposals for more information by following this link:

TB Elimination Alliance Announces 2023 Mini-Grant Program Awardees

The Tuberculosis Elimination Alliance (TEA), led by the Association of Asian Pacific Community Health Organizations (AAPCHO), Asian & Pacific Islander American Health Forum (APIAHF), Hepatitis B Foundation (HBF), and Stop TB USA, with the support of the Centers for Disease Control and Prevention’s (CDC) Division of TB Elimination, announced that it awarded a total of $250,000 to 12 community health organizations serving Asian, Asian American (A/AA), Native Hawaiian, and Pacific Islander (NH/PI), Hispanic/Latino and African American communities that are disproportionately impacted by tuberculosis (TB).


TEA offered a third cycle of 12 mini-grant awards totaling $250,000 to community providers that increase awareness and build capacity on TB testing and treatment. The newly awarded mini-grant recipients in this cycle are as follows:

  • Arkansas Coalition of Marshallese (Springdale, AR)
  • Asian Pacific Health Foundation (San Diego, CA)
  • EthnoMed (Seattle, WA)
  • Jericho Road Community Health Center (Buffalo, NY)
  • Midwest Asian Health Association (Chicago, IL)
  • Mission Neighborhood Health Center (San Francisco, CA)
  • Regional Pacific Islander Taskforce (San Francisco, CA)
  • Revive Community Health (Tempe, AZ)
  • Rural Women's Health Project (Gainesville, FL)
  • San Diego County Medical Society Foundation, dba Champions for Health (San Diego, CA)
  • Todu Guam Foundation, Ltd. (Tamuning, Guam)
  • We Are TB / Somos TB (National)

Since its inception in 2019, TEA has distributed over $800,000 in mini-grant funding to 36 organizations. TEA, our members, partners, and mini-grantees look forward to building on the progress that we have made so far towards TB elimination. 

For more information on TEA, please visit

Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections

Open Date (Earliest Submission Date): October 05, 2023

Expiration Date: July 17, 2026

This Notice of Special Interest (NOSI) encourages applications that seek to better understand Pulmonary Non-Tuberculous Mycobacteria (NTM) Infections and inform development of medical countermeasures. This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii.

For more information, click here

Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023

Due Dates: October 11, 2023

Open Date: Earliest Submission Date: September 11, 2023

The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.   

More information here

Peer Reviewed Medical Research Program (PRMRP)

The Peer Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service Members, Veterans, retirees, and their family members.

FY2023 Funding Mechanisms have been announced! The Congressionally Directed Topic Areas include:

  • Clinical Trial Award (CTA)
  • Discovery Award (DA)
  • Focused Program Award (FPA)
  • Investigator-Initiated Research Award (IIRA)
  • Lifestyle and Behavioral Health Interventions Research Award (LBIRA)
  • Technology/Therapeutic Development Award (TTDA)

Letter of Intent is Due: April 19th, 2023

Full Applications are Due: May 31st, 2023

Learn more about this opportunity at


Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission

Open Date (Earliest Submission Date): February 05, 2023

Expiration Date: January 08, 2026

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

For more information click here

Contract Solicitation: Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA)

The purpose of the proposed contract will be to provide a Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA), a resource to: (1) support the ability of laboratories (Labs) to reliably perform study-specified MTB tests; (2) evaluate MTB technologies and specimen processes for use in clinical investigations; and (3) disseminate technical and scientific data.

Notice ID: 75N93022R00015

  • Original Published Date: Aug 31, 2022 08:19 am EDT
  • Original Date Offers Due: Nov 30, 2022 03:00 pm EST

For more info, click here

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

Open Date (Earliest Submission Date): April 01, 2023

Expiration Date: May 02, 2025

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS research related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Projects must be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been described most recently in NOT-OD-20-018.

For more information click here

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01, Clinical Trial Not Allowed)

Open Date (Earliest Submission Date): November 07, 2022

Expiration Date: December 08, 2024

The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and their effect on immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies.

For more information click here